Microbot Medical Inc MBOT 深 滬
等待開盤 12-10 09:30:00 美东时间
2.46
+0.100
+4.24%
華盛通- 最 高2.48
- 今 開2.38
- 成交量 178.83万股
- 最 低 2.33
- 昨 收 2.36
- 總市值 1.65亿
- 52周最高 4.67
- 市盈率 靜 --
- 換手率 2.66%
- 52周最低 0.962
- 委 比 -57.94%
- 總股本 6715.80万
- 歷史最高 149.10
- 量 比 0.55
- 振 幅 6.36%
- 歷史最低 0.82
- 每 手 1
- 風險率 0.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
12-04 09:38
Roth Capital Initiates Coverage On Microbot Medical with Buy Rating, Announces Price Target of $5.5
Roth Capital analyst Kyle Bauser initiates coverage on Microbot Medical (NASDAQ:MBOT) with a Buy rating and announces Price Target of $5.5.
12-04 01:58
美股大行评级 | 美银证券下调哔哩哔哩目标价至31美元；高盛下调诺和诺德目标价至54美元
今日重点评级关注：Benchmark：维持Grupo Televisa"买入"评级，目标价从9美元升至10美元；Truist Securities：维持迪尔股份"买入"评级，目标价从609美元升至612美元
12-01 14:33
美股牛股 | Arrowhead制药飙升23%，行业首个微粒血症商用药物获FDA批准；DeFi大涨20%
Arrowhead制药飙升23%，行业首个微粒血症商用药物获FDA批准，最新财报强劲超预期；DeFi大涨20%，公司宣布QCAD数字信托获批为加拿大首个合规的加元稳定币>>
11-27 16:04
Microbot Medical Says Emory University Hospital Adopts LIBERTY For Patient Care; Microbot Collaborates With Emory To Establish Endovascular Robotics Program In Interventional Radiology
Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, announced that Emory University Hospital, a nationally recognized academic medical center in Atlanta,
11-26 21:35
Microbot Medical Announces Commercial Availability Of LIBERTY Robotic System In U.S.
Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that its LIBERTY® System, the first FDA cleared single-use, remotely operated
11-05 21:34
Microbot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting
Microbot Medical Inc. will exhibit its LIBERTY® Endovascular Robotic System at the upcoming CIO symposium in Miami, marking its first commercial presence post-FDA clearance. The company has completed its commercial leadership team recruitment, with Justin Bourne, Dani Kulp, and Xiomara Ortiz joining to support the launch. The LIBERTY® System is set to commence its limited market release during Q4 2025, following successful logistics preparation.
10-16 12:30
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
Microbot Medical Partners With U.S. Based 3PL Company To Support Commercialization Of FDA-Cleared LIBERTY System
The Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support The Company is on Track to Commence the Launch of LIBERTY® during Q4 This
10-14 20:32
Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
Microbot Medical Inc. partners with a U.S. 3PL company to support the commercialization of its FDA-cleared LIBERTY® Endovascular Robotic System. The limited market release is expected in Q4 2025, with a broader launch planned for April 2026. The partnership aims to enhance inventory management and customer support, leveraging the logistics provider’s expertise in the medical device industry. The company is focused on efficiently executing its go-...
10-14 12:30
